Welcome to our dedicated page for Strata Critical Medical news (Ticker: SRTA), a resource for investors and traders seeking the latest updates and insights on Strata Critical Medical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Strata Critical Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Strata Critical Medical's position in the market.
Strata Critical Medical (NASDAQ:SRTA), previously Blade Air Mobility (NASDAQ:BLDE), has announced its participation in the upcoming 2025 Jefferies Industrials Conference. The company's Co-CEO and CFO, Will Heyburn, will deliver a presentation on September 4, 2025, at 11:30 AM ET.
Investors can access the presentation via webcast, with a replay available afterward on the company's investor relations website at ir.stratacritical.com/news-events.
Strata Critical Medical (NASDAQ:SRTA), formerly Blade Air Mobility (NASDAQ:BLDE), has completed the sale of its Passenger business to Joby Aviation (NYSE:JOBY). The transaction includes stock-based upfront payment, with potential additional consideration of up to $35 million tied to employee retention and financial performance targets, plus up to $10 million in indemnity holdbacks.
The company has rebranded to focus exclusively on organ logistics and medical services, leveraging its coast-to-coast asset-light aircraft network. For FY2025, Strata projects revenue of $160-170 million with double-digit Adjusted EBITDA, and expects quarterly corporate expenses to decrease to $3.5 million by Q4 2025.
FAQ
What is the current stock price of Strata Critical Medical (SRTA)?
